"目录号: HY-13678
Meropenem是碳青霉烯类广谱抗菌素。
相关产品
G-418 disulfate-Anisomycin-Salinomycin-Avibactam sodium-Vancomycin hydrochloride-Hygromycin B-Bleomycin sulfate-Ciprofloxacin-Minocycline hydrochloride-Ampicillin sodium-Tetracycline hydrochloride-Tebipenem-Kanamycin sulfate-Solithromycin-Tedizolid-
生物活性
Description
Meropenem is a carbapenem antibiotic, which displaying a broad spectrum of antibacterial activity.Target: AntibacterialMeropenem, a new parenteral carbapenem demonstrated increased activity as compared to imipenem against 336 strains of Neisseria gonorrhoeae, 119 strains of Haemophilus influenzae, and 110 strains of H. Ceftriaxone and ciprofloxacin demonstrated activity superior to that of both carbapenems while the activity of ceftazidime was similar to that of meropenem [1]. Meropenem, like imipenem and various experimental penems, may overcome the resistance problems presented by Class I beta-lactamases [2]. MEROPENEM was rapidly penetrated to the pleural effusion and was retained for a more prolonged time in the pleural effusion than in the blood of patients with accumulated pleural effusion, and it suggested the usefulness of MEROPENEM in antibacterial therapy for patients with pleurisy causing accumulation of pleural effusion [3].Clinical indications: Appendicitis; Bacterial infection; Bacterial meningitis; Bacterial pneumonia; Bacterial respiratory tract infection; Bacterial skin infection; Bacterial urinary tract infection; Bacteroides fragilis infection; Bacteroides infection; Bacteroides thetaiotaomicron infection; Complicated skin and skin structure infectionFDA Approved Date: July 1996Toxicity: In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.
Clinical Trial
St. Michael's Hospital, Toronto-Sunnybrook Health Sciences Centre-University of Toronto
Cystic Fibrosis Pulmonary Exacerbation
May 2010
PENTA Foundation-Chiesi Farmaceutici S.p.A.
Meningitis
February 2013
Phase 1-Phase 2
Joseph Kuti-Thrasher Research Fund-Hartford Hospital
Cystic Fibrosis-Pneumonia-Pseudomonas Aeruginosa Infection
February 2012
Phase 4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-The EMMES Corporation
Necrotizing Enterocolitis-Intra-abdominal Infection
June 2008
Phase 1-Phase 2
Huashan Hospital
Central Nervous System Infections
September 2008
Phase 4
Qingtao Zhou-Peking University Third Hospital
Lower Respiratory Tract Infection
July 2013
Phase 4
Sutep Jaruratanasirikul-Prince of Songkla University
Ventilator-Associated Pneumonia
January 2004
Phase 4
The University of Queensland
Bloodstream Infections
April 2015
Phase 4
Austin Health
Sepsis
April 2009
Sutep Jaruratanasirikul-Prince of Songkla University
Initial Phase of Severe Sepsis and Septic Shock
January 2013
Phase 4
PENTA Foundation-Chiesi Farmaceutici S.p.A.
Sepsis
September 2012
Phase 3
Mical Paul-European Commission-Rabin Medical Center
Gram-Negative Bacterial Infections
March 2013
Phase 4
Kompetenznetz Sepsis-AstraZeneca-Bayer
Severe Sepsis-Septic Shock
October 2007
Phase 3
The University of Queensland-International Society of Chemotherapy-Australian Society for Antimicrobials-Queensland Clinical Trials & Biostatistics Centre-Australasian Society for Infectious Diseases
Bloodstream Infections
February 2014
Phase 4
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-European Commission
Ventilator-associated Bacterial Pneumonia
May 2012
Phase 3
Hoffmann-La Roche
Urinary Tract Infections
July 11, 2017
Phase 1
University of Oxford-Mahidol University-Wellcome Trust
Melioidosis
December 2007
AstraZeneca
Pancreatitis
February 2002
Phase 4
PETHEMA Foundation
Allogenic Blood Stem Cell Transplantation-Febrile Neutropenia
November 2002
University of Padova
Cirrhosis-Ascites-Nosocomial Spontaneous Bacterial Peritonitis
October 2010
Phase 2-Phase 3
Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections-Complicated Appendicitis
October 13, 2016
Phase 3
Cubist Pharmaceuticals LLC
Complicated Intra-abdominal Infection
December 1, 2011
Phase 3
AstraZeneca
Nosocomial Pneumonia (NP)-Ventilator-associated Pneumonia (VAP)
April 2013
Phase 3
AstraZeneca
Sepsis
January 2002
Phase 4
Mansoura University
Late Onset Neonatal Sepsis
August 2013
Phase 3
Cubist Pharmaceuticals LLC
Nosocomial Pneumonia
September 23, 2014
Phase 3
Janssen Research & Development, LLC
Abscess, Intra-Abdominal-Abdominal Abscess-Abdomen, Acute-Abdominal Pain-Appendicitis-Rupture-Infection-Intestinal Perforation-Peritonitis-Ileus
December 2010
Phase 3
Mahidol University
Drug Safety
May 2011
Phase 4
Cubist Pharmaceuticals LLC
Complicated Intra-abdominal Infection
June 2010
Phase 2
Centre Hospitalier Universitaire de Besancon
Septic Shock
September 2016
Phase 3
AstraZeneca-Forest Laboratories
Complicated Intra-Abdominal Infection
March 2012
Phase 3
The Medicines Company
Hospital-Acquired Bacterial Pneumonia-Ventilator-Associated Bacterial Pneumonia-Hospital-Acquired Pneumonia-Ventilator-Associated Pneumonia
February 2017
Phase 3
AstraZeneca
Complicated Intra-abdominal Infection
January 2013
Phase 3
Novexel Inc
Complicated Intra-Abdominal Infections
March 2009
Phase 2
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-Spanish Network for Research in Infectious Diseases
Infection Due to ESBL Escherichia Coli
July 2014
Phase 3
Hoffmann-La Roche
Healthy Volunteers
October 31, 2016
Phase 1
Task Foundation NPC-University Eduardo Mondlane-GlaxoSmithKline-Barcelona Centre for International Health Research-Research Center Borstel
Pulmonary Tuberculosis
September 2014
Phase 2
Johns Hopkins University
Tuberculosis, Pulmonary
September 1, 2017
Phase 2
Hoffmann-La Roche
Gram-negative Bacterial Infections
June 15, 2017
Phase 1
Merck Sharp & Dohme Corp.
Complicated Intra-Abdominal Infection
September 1, 2017
Phase 2
Achaogen, Inc.
Complicated Urinary Tract Infection-Acute Pyelonephritis
January 2016
Phase 3
AstraZeneca
Skin Infection-Abscess-Cellulitis
February 2001
Phase 3
Shionogi-Shionogi Inc.
Healthcare-associated Pneumonia (HCAP)-Hospital Acquired Pneumonia (HAP)-Ventilator Associated Pneumonia (VAP)
July 30, 2017
Phase 3
Merck Sharp & Dohme Corp.
Urinary Tract Infections
December 2008
Phase 3
AstraZeneca
Pancreatitis, Acute Necrotizing
February 2003
Phase 4
University of Michigan
Pneumonia-Blood Stream Infection
October 2012
Phase 3
AstraZeneca-PRA Health Sciences
Complicated Intra-abdominal Infections
July 31, 2015
Phase 2
